These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9042392)

  • 21. Isradipine decreases the hemodynamic response of cocaine and methamphetamine results from two human laboratory studies: results from two human laboratory studies.
    Johnson BA; Wells LT; Roache JD; Wallace C; Ait-Daoud N; Wang Y
    Am J Hypertens; 2005 Jun; 18(6):813-22. PubMed ID: 15925741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d-methamphetamine's positive subjective effects: a preliminary study.
    Johnson BA; Roache JD; Bordnick PS; Ait-Daoud N
    Psychopharmacology (Berl); 1999 Jun; 144(3):295-300. PubMed ID: 10435398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discrimination of a single dose of morphine followed by naltrexone: substitution of other agonists for morphine and other antagonists for naltrexone in a rat model of acute dependence.
    Holtzman SG
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1033-41. PubMed ID: 12604679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcium channel antagonist isradipine attenuates cocaine-induced motor activity in rats: correlation with brain monoamine levels.
    Mills K; Arsah TA; Ali SF; Shockley DC
    Ann N Y Acad Sci; 1998 May; 844():201-7. PubMed ID: 9668678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Applications of isradipine in human addiction studies: A systematic literature review.
    Natal S; Young CC; Kaur K; Gebhardt ES; Perrone A; Morikawa H; Tirado C; Smits JAJ
    Exp Clin Psychopharmacol; 2023 Apr; 31(2):507-522. PubMed ID: 36595455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addictive agents and intracranial stimulation (ICS): novel antagonists and agonists of morphine and pressing for ICS.
    Bermudez-Rattoni F; Cruz-Morales S; Reid LD
    Pharmacol Biochem Behav; 1983 May; 18(5):777-84. PubMed ID: 6856650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of oral and implant naltrexone outcomes at 12 months.
    Colquhoun R; Tan DY; Hull S
    J Opioid Manag; 2005; 1(5):249-56. PubMed ID: 17319558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Naltrindole, a selective delta-opioid receptor antagonist, potentiates the lethal effects of cocaine by a central mechanism of action.
    Patterson AB; Gordon FJ; Holtzman SG
    Eur J Pharmacol; 1997 Aug; 333(1):47-54. PubMed ID: 9311660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term efficacy of Disulfiram or Naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study.
    Grassi MC; Cioce AM; Giudici FD; Antonilli L; Nencini P
    Pharmacol Res; 2007 Feb; 55(2):117-21. PubMed ID: 17174102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment advances for cocaine-induced ischemic stroke: focus on dihydropyridine-class calcium channel antagonists.
    Johnson BA; Devous MD; Ruiz P; Ait-Daoud N
    Am J Psychiatry; 2001 Aug; 158(8):1191-8. PubMed ID: 11481148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study.
    Simuni T; Borushko E; Avram MJ; Miskevics S; Martel A; Zadikoff C; Videnovic A; Weaver FM; Williams K; Surmeier DJ
    Mov Disord; 2010 Dec; 25(16):2863-6. PubMed ID: 20818667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the calcium antagonist isradipine on cocaine intravenous self-administration in rats.
    Martellotta MC; Kuzmin A; Muglia P; Gessa GL; Fratta W
    Psychopharmacology (Berl); 1994 Jan; 113(3-4):378-80. PubMed ID: 7862848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A risk-benefit assessment of naltrexone in the treatment of alcohol dependence.
    Berg BJ; Pettinati HM; Volpicelli JR
    Drug Saf; 1996 Oct; 15(4):274-82. PubMed ID: 8905252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of isradipine, an L-type calcium channel blocker on permanent and transient focal cerebral ischemia in spontaneously hypertensive rats.
    Campbell CA; Mackay KB; Patel S; King PD; Stretton JL; Hadingham SJ; Hamilton TC
    Exp Neurol; 1997 Nov; 148(1):45-50. PubMed ID: 9398449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain MRI and neurological deficit measurements in focal stroke: rapid throughput validated with isradipine.
    Lenhard SC; Strittmatter R; Price WJ; Chandra S; White RF; Barone FC
    Pharmacology; 2008; 81(1):1-10. PubMed ID: 17726342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of diffusion-weighted MRI and neurological deficit scores to demonstrate beneficial effects of isradipine in a rat model of focal ischemia.
    Chandra S; White RF; Everding D; Feuerstein GZ; Coatney RW; Sarkar SK; Barone FC
    Pharmacology; 1999 Jun; 58(6):292-9. PubMed ID: 10325574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.
    Yodfat Y; Bar-On D; Amir M; Cristal N
    J Hum Hypertens; 1996 Feb; 10(2):117-22. PubMed ID: 8867566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcium channel blockers antagonize some of cocaine's cardiovascular effects, but fail to alter cocaine's behavioral effects.
    Schindler CW; Tella SR; Prada J; Goldberg SR
    J Pharmacol Exp Ther; 1995 Feb; 272(2):791-8. PubMed ID: 7853196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.
    Ling W; Hillhouse MP; Saxon AJ; Mooney LJ; Thomas CM; Ang A; Matthews AG; Hasson A; Annon J; Sparenborg S; Liu DS; McCormack J; Church S; Swafford W; Drexler K; Schuman C; Ross S; Wiest K; Korthuis PT; Lawson W; Brigham GS; Knox PC; Dawes M; Rotrosen J
    Addiction; 2016 Aug; 111(8):1416-27. PubMed ID: 26948856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic very low dose naltrexone administration attenuates opioid withdrawal expression.
    Mannelli P; Gottheil E; Peoples JF; Oropeza VC; Van Bockstaele EJ
    Biol Psychiatry; 2004 Aug; 56(4):261-8. PubMed ID: 15312814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.